Nifty
Sensex
:
:
14310.80
47883.38
-524.05 (-3.53%)
-1707.94 (-3.44%)

Pharmaceuticals & Drugs

Rating :
38/99

BSE: 532660 | NSE: VIVIMEDLAB

16.20
12-Apr-2021
  • Open
  • High
  • Low
  • Previous Close
  •  17.10
  •  17.10
  •  15.85
  •  17.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  262907
  •  43.00
  •  23.35
  •  9.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 134.32
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,026.52
  • N/A
  • 0.18

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 32.79%
  • 4.74%
  • 41.33%
  • FII
  • DII
  • Others
  • 3.1%
  • 0.12%
  • 17.92%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.79
  • -4.68
  • -3.70

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -22.74
  • -50.60
  • -49.55

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.47
  • 3.45
  • 2.24

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.77
  • 0.64
  • 0.25

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.71
  • 10.46
  • 13.63

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
277.94
197.70
40.59%
221.74
281.07
-21.11%
322.79
344.21
-6.22%
235.82
348.08
-32.25%
Expenses
299.80
206.57
45.13%
206.34
284.53
-27.48%
276.21
303.11
-8.87%
256.48
326.69
-21.49%
EBITDA
-21.86
-8.87
-
15.41
-3.46
-
46.58
41.10
13.33%
-20.66
21.39
-
EBIDTM
-7.87%
-4.49%
6.95%
-1.23%
14.43%
11.94%
-8.76%
6.14%
Other Income
4.34
2.09
107.66%
1.89
2.48
-23.79%
1.81
1.27
42.52%
2.42
6.10
-60.33%
Interest
16.13
16.48
-2.12%
13.65
15.59
-12.44%
14.88
12.11
22.87%
14.71
12.83
14.65%
Depreciation
16.52
15.62
5.76%
17.56
16.90
3.91%
17.29
16.95
2.01%
17.48
16.05
8.91%
PBT
-50.17
-38.88
-
-13.91
-33.47
-
16.22
13.31
21.86%
-50.44
-1.40
-
Tax
-0.62
-6.80
-
-0.29
-7.12
-
3.38
3.16
6.96%
10.40
-1.41
-
PAT
-49.55
-32.07
-
-13.62
-26.35
-
12.84
10.15
26.50%
-60.84
0.02
-
PATM
-17.83%
-16.22%
-6.14%
-9.38%
3.98%
2.95%
-25.80%
0.00%
EPS
-5.98
-3.87
-
-1.64
-3.18
-
1.55
1.22
27.05%
-7.34
0.00
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
1,058.29
1,058.80
1,315.17
1,185.66
1,461.91
1,345.63
1,380.10
1,350.83
1,108.80
668.31
416.00
Net Sales Growth
-9.63%
-19.49%
10.92%
-18.90%
8.64%
-2.50%
2.17%
21.83%
65.91%
60.65%
 
Cost Of Goods Sold
420.91
462.55
518.40
479.67
536.28
624.05
646.23
656.33
513.27
337.39
236.97
Gross Profit
637.38
596.24
796.77
705.99
925.63
721.58
733.88
694.51
595.52
330.93
179.03
GP Margin
60.23%
56.31%
60.58%
59.54%
63.32%
53.62%
53.18%
51.41%
53.71%
49.52%
43.04%
Total Expenditure
1,038.83
1,052.24
1,146.24
984.93
1,057.46
1,122.68
1,158.21
1,166.29
928.00
538.02
329.44
Power & Fuel Cost
-
42.46
42.77
34.73
34.78
38.26
46.70
51.39
44.06
22.33
11.08
% Of Sales
-
4.01%
3.25%
2.93%
2.38%
2.84%
3.38%
3.80%
3.97%
3.34%
2.66%
Employee Cost
-
233.36
241.76
197.78
189.98
176.94
184.43
162.66
50.33
32.19
19.97
% Of Sales
-
22.04%
18.38%
16.68%
13.00%
13.15%
13.36%
12.04%
4.54%
4.82%
4.80%
Manufacturing Exp.
-
196.36
217.39
176.69
175.06
167.31
179.26
182.37
230.50
91.61
32.06
% Of Sales
-
18.55%
16.53%
14.90%
11.97%
12.43%
12.99%
13.50%
20.79%
13.71%
7.71%
General & Admin Exp.
-
96.13
111.52
78.75
93.93
95.26
76.30
86.64
69.34
31.42
15.96
% Of Sales
-
9.08%
8.48%
6.64%
6.43%
7.08%
5.53%
6.41%
6.25%
4.70%
3.84%
Selling & Distn. Exp.
-
13.82
14.41
16.66
15.39
20.86
25.29
26.91
20.50
23.09
11.26
% Of Sales
-
1.31%
1.10%
1.41%
1.05%
1.55%
1.83%
1.99%
1.85%
3.45%
2.71%
Miscellaneous Exp.
-
7.56
0.00
0.65
12.03
0.00
0.00
0.00
0.00
0.00
11.26
% Of Sales
-
0.71%
0%
0.05%
0.82%
0%
0%
0%
0%
0%
0.51%
EBITDA
19.47
6.56
168.93
200.73
404.45
222.95
221.89
184.54
180.80
130.29
86.56
EBITDA Margin
1.84%
0.62%
12.84%
16.93%
27.67%
16.57%
16.08%
13.66%
16.31%
19.50%
20.81%
Other Income
10.46
11.95
33.97
23.76
8.09
23.63
8.02
35.90
26.33
2.68
1.00
Interest
59.37
61.03
70.06
82.35
67.79
85.26
86.20
67.46
50.44
28.37
22.10
Depreciation
68.85
66.95
66.79
56.42
58.28
61.39
66.18
66.12
58.81
26.79
10.20
PBT
-98.30
-109.47
66.05
85.71
286.48
99.93
77.54
86.86
97.88
77.82
55.26
Tax
12.87
-0.36
8.68
9.62
72.50
16.26
5.49
20.47
14.29
14.68
6.43
Tax Rate
-13.09%
0.33%
13.14%
11.22%
25.31%
16.27%
7.08%
23.57%
14.60%
18.86%
11.64%
PAT
-111.17
-109.11
57.37
77.94
213.97
83.67
72.05
66.39
83.58
63.14
48.83
PAT before Minority Interest
-111.17
-109.11
57.37
76.09
213.97
83.67
72.05
66.39
83.58
63.14
48.83
Minority Interest
0.00
0.00
0.00
1.85
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-10.50%
-10.31%
4.36%
6.57%
14.64%
6.22%
5.22%
4.91%
7.54%
9.45%
11.74%
PAT Growth
0.00%
-
-26.39%
-63.57%
155.73%
16.13%
8.53%
-20.57%
32.37%
29.31%
 
EPS
-13.41
-13.16
6.92
9.40
25.81
10.09
8.69
8.01
10.08
7.62
5.89

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
834.59
943.79
1,226.40
734.21
585.15
559.24
560.36
509.14
474.79
196.71
Share Capital
341.80
341.73
341.73
16.20
80.15
80.15
80.15
80.01
144.88
10.16
Total Reserves
492.79
602.07
884.67
718.01
505.00
479.09
477.84
426.77
327.54
177.68
Non-Current Liabilities
590.94
489.65
356.86
503.86
561.11
538.36
532.58
449.68
360.72
148.25
Secured Loans
414.68
369.08
275.90
396.25
206.75
436.44
378.81
255.19
258.03
131.90
Unsecured Loans
55.71
55.72
49.30
57.07
50.52
46.94
40.92
41.73
53.35
0.00
Long Term Provisions
5.14
9.21
7.03
2.19
3.57
3.17
5.16
1.47
1.06
1.69
Current Liabilities
770.36
888.93
790.23
817.39
897.41
800.86
744.42
610.73
463.69
242.44
Trade Payables
226.50
294.42
201.99
178.59
166.74
188.71
190.49
166.28
156.86
44.06
Other Current Liabilities
101.78
227.11
147.64
179.92
285.85
176.38
138.78
116.10
40.79
4.68
Short Term Borrowings
418.51
332.30
385.16
381.47
407.76
389.38
375.43
301.13
232.82
175.08
Short Term Provisions
23.56
35.10
55.43
77.41
37.06
46.39
39.71
27.22
33.21
18.61
Total Liabilities
2,195.89
2,322.37
2,385.77
2,055.46
2,043.67
1,898.46
1,837.36
1,569.55
1,299.20
587.40
Net Block
1,045.12
964.92
1,035.36
878.90
814.17
813.47
807.92
709.04
595.35
264.29
Gross Block
1,271.07
1,156.58
1,128.64
915.77
1,663.33
1,599.11
1,526.04
1,329.52
1,167.48
812.71
Accumulated Depreciation
225.95
191.65
93.29
36.87
849.16
785.64
718.12
620.49
572.13
548.42
Non Current Assets
1,220.61
1,091.77
1,103.83
961.04
911.03
906.45
846.28
736.20
604.41
266.01
Capital Work in Progress
89.28
122.31
65.27
76.13
94.17
90.28
38.12
26.92
8.37
1.73
Non Current Investment
85.71
2.51
2.70
2.71
2.69
2.70
0.24
0.24
0.70
0.00
Long Term Loans & Adv.
0.00
1.52
0.00
2.81
0.00
0.00
0.00
0.00
0.00
0.00
Other Non Current Assets
0.50
0.50
0.50
0.50
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
975.28
1,230.61
1,281.94
1,094.42
1,132.60
991.96
970.90
815.08
647.14
314.68
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
501.91
563.69
540.17
483.97
490.80
431.43
426.66
340.26
247.88
84.47
Sundry Debtors
249.07
356.11
275.43
200.14
326.24
329.58
347.83
308.23
221.61
127.56
Cash & Bank
50.49
95.31
99.03
55.47
30.96
26.67
34.57
23.96
36.34
11.10
Other Current Assets
173.82
30.75
29.59
22.53
284.61
204.28
161.84
142.64
141.32
91.55
Short Term Loans & Adv.
140.96
184.76
337.73
332.31
272.88
185.21
139.50
119.82
141.09
89.45
Net Current Assets
204.92
341.68
491.71
277.03
235.19
191.10
226.47
204.35
183.45
72.25
Total Assets
2,195.89
2,322.38
2,385.77
2,055.46
2,043.67
1,898.45
1,837.36
1,569.55
1,299.21
587.39

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
79.56
422.14
21.42
57.96
154.12
140.48
-117.65
90.11
45.17
23.89
PBT
-109.47
66.05
85.71
286.48
99.93
77.54
86.86
97.88
77.81
55.26
Adjustment
125.89
134.05
135.90
124.15
101.94
111.32
101.31
80.43
55.16
32.30
Changes in Working Capital
83.08
237.03
-158.14
-315.94
-47.75
-48.38
-305.83
-94.13
-87.81
-63.67
Cash after chg. in Working capital
99.50
437.13
63.48
94.69
154.12
140.48
-117.65
84.18
45.17
23.89
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-19.94
-14.99
-42.06
-36.73
0.00
0.00
0.00
5.93
0.00
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-196.01
-88.87
-163.53
-68.49
-190.42
-106.71
-291.11
-169.59
-424.15
-72.39
Net Fixed Assets
9.10
-15.53
38.52
-25.51
-6.97
-49.04
-16.56
-128.68
-148.52
-26.78
Net Investments
0.03
64.34
-64.27
142.45
0.00
-2.50
-132.00
-8.38
-83.77
0.09
Others
-205.14
-137.68
-137.78
-185.43
-183.45
-55.17
-142.55
-32.53
-191.86
-45.70
Cash from Financing Activity
72.44
-337.80
185.66
35.05
40.59
-41.67
419.37
67.10
404.22
53.98
Net Cash Inflow / Outflow
-44.02
-4.53
43.56
24.51
4.29
-7.90
10.62
-12.38
25.24
5.47
Opening Cash & Equivalents
94.50
99.03
55.47
30.96
26.67
34.57
23.96
36.34
11.10
5.62
Closing Cash & Equivalent
50.49
94.50
99.03
55.47
30.96
26.67
34.57
23.96
36.34
11.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
56.85
70.35
104.60
85.93
64.20
61.00
58.36
52.74
42.03
35.45
ROA
-4.83%
2.44%
3.43%
10.44%
4.25%
3.86%
3.90%
5.83%
6.69%
9.36%
ROE
-20.75%
7.95%
9.76%
35.18%
16.50%
14.90%
14.81%
23.34%
26.70%
31.18%
ROCE
-2.69%
7.03%
9.04%
21.86%
11.93%
10.91%
11.93%
13.83%
14.29%
17.80%
Fixed Asset Turnover
0.87
1.15
1.16
1.13
0.82
0.88
0.95
0.89
0.67
0.76
Receivable days
104.31
87.64
73.20
65.71
88.94
89.58
88.63
87.21
95.35
97.13
Inventory Days
183.67
153.18
157.64
121.69
125.08
113.47
103.61
96.80
90.76
71.87
Payable days
92.05
79.66
70.90
60.76
60.42
57.00
57.11
62.91
65.22
47.96
Cash Conversion Cycle
195.94
161.15
159.93
126.64
153.61
146.05
135.14
121.10
120.89
121.04
Total Debt/Equity
1.18
1.05
0.69
1.45
1.63
1.81
1.66
1.36
1.33
1.70
Interest Cover
-0.79
1.94
2.04
5.23
2.17
1.90
2.29
2.94
3.74
3.50

News Update:


  • Vivimed Labs gets approval from Uzbekistan government for two products
    8th Mar 2021, 14:04 PM

    The company has received approval for Bilastin tablets

    Read More
  • Vivimed Labs gets approval for 1 product from Uzbekistan Government
    22nd Feb 2021, 14:05 PM

    Paracetamol is also known as acetaminophen, is a medication used to treat pain and fever

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.